Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : RNAi -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (471)	8/14/2006 4:22:23 AM
From: Thomas	Read Replies (1) \| Respond to of 671

Thanks, Tuck. I wonder about Alnylam's decision to cut bait on their AMD candidate- they said a the time it was based on the competitive environment -- the efficacy data of PIII VEGF targeted drugs. And Acuity is still ahead of Sirna on AMD too. Here is a pretty good backgrounder/overview article of the field of RNAi programs and companies: dddmag.com Prompted me to re-look at Calando (owned by ARWR) and Nastech (NSTK), as well as updating my view on ALNY. With a handful of stocks, you can own the industry. But then, it comes down to delivery... Cheers, Tom